---
document_datetime: 2023-09-21 18:03:40
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/olanzapine-cipla-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: olanzapine-cipla-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.8534864
conversion_datetime: 2025-12-25 09:18:21.019024
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Olanzapine Cipla

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------|-----------|
| IB/0014              | Update of section 4.8 of the SmPC and relevant section of the PL to include 'amnesia, epistaxis, abdominal distension, arthralgia, GGT high, uric acid high, pyrexia and dysarthria', as new undesirable effects. The frequencies of currently labelled undesirable effects have also been revised throughout sections 4.4 and 4.8 of the SmPC and relevant sections of the PL. In addition, Annex II has been brought in line with the latest QRD template. product | 28/11/2013                                                                       | SmPC, Annex II, and PL           |           |

A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Medicinal product no longer authorised

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |                    |               |                                  | authorised                                                                                                                                                                                                                                                                                |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0015 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                | 24/10/2013         | n/a           |                                  |                                                                                                                                                                                                                                                                                           |
| T/0013    | Transfer of MA from Neopharma Ltd. 57 High Street, Odiham Hampshire RG29 1LF United Kingdom to Cipla (EU) Ltd Hillbrow Road Esher Surrey KT10 9NW                                                                                                              | 02/04/2013 product | 14/05/2013 no | SmPC, Labelling and PL longer    |                                                                                                                                                                                                                                                                                           |
| R/0011    | Transfer of Marketing Authorisation Renewal of the marketing authorisation. Medicinal                                                                                                                                                                          | 19/07/2012         | 01/10/2012    | SmPC, Annex II, Labelling and PL | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP was of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |                        | considered that the benefit risk profile of Olanzapine Neopharma continues to be favourable.   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|------------------------------------------------------------------------------------------------|
| IAIN/0010/G | This was an application for a group of variations. B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes                                                                                                                                         | 03/05/2012 | n/a                    | authorised                                                                                     |
| IAIN/0012/G | place This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing product                                                                                                                                                                                                           | 03/05/2012 | n/a Annex II no longer | and PL                                                                                         |
| IB/0009     | Following PhVWP/CHMP conclusions of October 2011, update of the Summary of Product Characteristics (SmPC) and Package Leaflet (PL) in line with the reference medicinal product regarding the inclusion of metabolic monitoring frequency examples following the assessment of the latest PSURs and RMP and to update the frequency of Venous thromboembolism (VTE) following PhVWP recommendation to include warnings about the risk of venous thromboembolism. In addition, corrections in the Danish, Estonian, Medicinal | 07/02/2012 | n/a SmPC               | and PL                                                                                         |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | Finnish, French, Latvian, Polish, Portuguese and Slovenian annexes have been made in line with the reference product Zyprexa. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                       |            |        | authorised         |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------|--------------------|
| IB/0008 | Following PhVWP/CHMP conclusions of June 2011, update of the Summary of Product Characteristics (SmPC) and Package Leaflet (PL) in line with the reference medicinal product regarding the use of antipsychotics during the third trimester of pregnancy and risk of abnormal muscle movements and/or withdrawal symptoms in newborns in accordance with the PhVWP/CHMP class labelling recommended wording. In addition, corrections in the Bulgarian and Estonian annexes have been made. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH product | 03/01/2012 | n/a no | SmPC and PL longer |
| IB/0007 | Update of section 4.4 (deletion of a sentence in the warning related to hepatic function) and 4.8 (modification of the prolactin information in the footnote) of the Summary of Product Characteristics following assessment of the same change for the reference product. Additional changes have also been Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                             | 27/10/2010 | n/a    | SmPC and PL        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | made to the Product Information in accordance with the QRD templates (version 7.3.1). C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                    | authorised                                                                                                                                                                                                         |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0006 | Update of the sections 4.8 and 4.4 of the Summary of Product Characteristics (SPC) in line with the Product Information of the reference product regarding sudden cardiac death, urinary incontinence and information on elevated plasma prolactin concentrations and related clinical manifestations. Section 4 of the package leaflet has also been amended accordingly. Additionally, editorial changes were made in the relevant sections of the Product Information in line with the reference medicinal product. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO product | 22/03/2010 | n/a no     | SmPC and PL longer |                                                                                                                                                                                                                    |
| II/0005 | new additional data are submitted by the MAH Update to section 4.8 of the Summary of Product Characteristics (SPC) in line with the Product Information of the reference medicinal product. An editorial change was made in section 4.4 of the SPC. Update of Summary of Product Characteristics Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                       | 24/09/2009 | 13/10/2009 | SmPC               | The SPC was updated to align it with that of the reference medicinal product. This followed a change to the SPC of the reference medicinal product via the following procedure: Zyprexa (EMEA/H/C/000115/II/0099). |

<div style=\"page-break-after: always\"></div>

| II/0004   | Update to sections 4.4, 4.9 and 5.1 of the Summary of Product Characteristics (SPC) in line with the Product Information of the reference medicinal product Zyprexa.                                                                                                                       | 25/06/2009   | 16/07/2009           | SmPC                   | Following changes to the SPC of the reference medicinal product Zyprexa, sections 4.4, 4.9 and 5.1 of the Olanzapine Neopharma SPC were updated. Recommendations on monitoring of patients for signs and symptoms of hyperglycaemia, worsening of glucose control authorised                                                                                                                                                                                                                 |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0003   | Update of Section 4.8 of the SPC in line with the reference medicinal product. Some minor editorial changes have been introduced to keep the SPC in line with that for the reference product. Update of Summary of Product Characteristics and Package Leaflet                             | 23/10/2008   | 21/11/2008 no longer | SmPC                   | Following a change to the SPC of the reference medicinal product, Section 4.8 of the SPC of Olanzapine Neopharma were updated to align them with those of the reference medicinal product to include new data regarding changes in bodyweight, glucose and lipid levels over time in adults and adolescents. The summary of the above mentioned changes may be found in the EPARs (module 8B) of Zyprexa (II/92) and Zyprexa Velotab (II/61).                                                |
| II/0002   | Update of Sections 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SPC in line with the reference medicinal product. The Product Information was updated in accordance with the latest QRD templates. Update of Summary of Product Characteristics, Labelling and Package Leaflet Medicinal product | 24/07/2008   | 02/09/2008           | SmPC, Labelling and PL | Following a change to the SPC of the reference medicinal product, Sections 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SPC of Olanzapine Neopharma were updated to align them with those of the reference medicinal product to include data from studies conducted in adolescent population with schizophrenia and bipolar I disorder (manic or mixed episodes). The summary of the above mentioned changes may be found in the EPARs (module 8B) of Zyprexa (II/83) and Zyprexa Velotab (II/52). |

<div style=\"page-break-after: always\"></div>

<!-- image -->